Pharmafocus: Advances in Oncology available now!
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, oncology, pharmafocus supplement
The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …
Top Ten articles in the Pharma Industry this week
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of …
€10.2 billion lost every year across the EU due to fake medicines
September 30, 2016Manufacturing and Production, Medical Communications EU, European Union Intellectual Property Office, France, Germany, Italy, Spain, united kingdom
A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic
September 30, 2016Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo
The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
GSK appoints Brian McNamara chief of consumer health division
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brian McNamara, Emma Walmsley, GlaxoSmithKline
GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement …
AbbVie opens its $300 million manufacturing plant in Singapore
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore
AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …
The October issue of Pharmafocus is now live!
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Pharmafocus new issue
The latest edition of Pharmafocus is available online now.
Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin
The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
Novo Nordisk to cut 2% of its entire workforce
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Denmark, Novo Nordisk, diabetes, insulin, job cuts, job losses
Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …
NICE approves Bayer’s Eylea for NHS use
September 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE
Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …
GW Pharma releases positive data on cannabidiol-based Phase III trial
September 28, 2016Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …
Malaysian pharmaceutical market set to grow to $3.6 billion by 2020
September 28, 2016Research and Development
The report, by GlobalData, states that the primary reasons behind this growth are linked to medical tourism, a lack of …
AbbVie and Eisai celebrate approval of new Humira indication
September 28, 2016Research and Development, Sales and Marketing AbbVie, Eisai, Humira
AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …
Zuckerberg appoints AstraZeneca’s Cornelia Bargmann
September 28, 2016Research and Development AstraZeneca, Facebook, Mark Zuckerberg, Priscilla Chan
Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …
80% of Chinese clinical trials’ data fabricated
September 28, 2016Manufacturing and Production, Research and Development China, Fabrication, corruption, report
The government review of clinical trial practise involved 1,622 programs of new pharmaceutical drugs waiting upon government approval to begin …
Provisional NICE recommendation for Gilead’s Hepatitis C treatment
September 28, 2016Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …
Merck elects Isabel De Paoli as CSO
September 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Amgen’s Kyprolis disappoints in Phase III trial
September 27, 2016Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III
Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …
Kite Pharma flying high after promising Car-T trial
September 27, 2016Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma
Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
